1529-0131/asset/olbannerleft.gif?v=1&s=897b81612b4ad6cae003112184adc709261d5f61)
1529-0131/asset/olbannerright.gif?v=1&s=04654f5ea3cbb01656383e0c0d04b16fd0a9a896)
Research Article
Variability in the efficacy of interferon-α in Erdheim-Chester disease by patient and site of involvement: Results in eight patients
Article first published online: 28 SEP 2006
DOI: 10.1002/art.22165
Copyright © 2006 by the American College of Rheumatology
1529-0131/asset/cover.gif?v=1&s=104d5c2bb8ef72deba26790b855af7ab80697a0e "Arthritis & Rheumatism")
Additional Information
How to Cite
Haroche, J., Amoura, Z., Trad, S. G., Wechsler, B., Cluzel, P., Grenier, P. A. and Piette, J.-C. (2006), Variability in the efficacy of interferon-α in Erdheim-Chester disease by patient and site of involvement: Results in eight patients. Arthritis & Rheumatism, 54: 3330–3336. doi: 10.1002/art.22165
Publication History
- Issue published online: 28 SEP 2006
- Article first published online: 28 SEP 2006
- Manuscript Accepted: 17 JUL 2006
- Manuscript Received: 21 NOV 2005
- Abstract
- Article
- References
- Cited By
Abstract
Objective
Erdheim-Chester disease (ECD) is a rare, non-Langerhans form of histiocytosis of unknown origin, characterized by infiltration of tissues by spumous histiocytes. ECD features heterogeneous systemic manifestations, and the general prognosis remains poor despite various treatment options.
Methods
We treated 8 patients with multisystemic ECD with subcutaneous interferon-α (IFNα) at a dosage of 3–9 × 106 units 3 times weekly, for a median duration of 23 months (range 1–46 months).
Results
Treatment was generally well tolerated, and side effects remained limited to fever following injections. Treatment was discontinued in 1 patient, because of severe depression. During treatment, some manifestations of ECD disappeared (i.e., xanthelasma, exophthalmos, papilledema, and intracranial hypertension). The efficacy of IFNα on cardiovascular ECD was variable, however. Treatment resulted in partial regression of “coated aorta” in some cases and clear failure in others; 2 patients died. The level of C-reactive protein diminished sharply in 5 patients.
Conclusion
IFNα might be a valuable first-line therapy for prolonged treatment of ECD. However, the efficacy of IFNα varies among patients and according to the sites of disease involvement, and symptoms may fail to respond to treatment, especially in patients with severe multisystemic forms of ECD with central nervous system and cardiovascular involvement.